Skip to content
Erudio Health
menu
Clinical trial · no report yet · Phase 3

AVANZAR

Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations

  • NCT05687266 ↗
  • Active not recruiting
  • AstraZeneca
  • 26 commentary sources found
  • Standard

We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.

Commentary we found

Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.

ChannelFound
Podcasts12
YouTube11
X threads3

The trial

ClinicalTrials.gov
Official title
A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First-line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR)
Phase
Phase 3
Status
Active not recruiting
Conditions
NSCLC
Interventions
Datopotamab deruxtecan; Durvalumab; Carboplatin; Pembrolizumab; Cisplatin; Pemetrexed; Paclitaxel
Arms
  • Dato-DXd + Durvalumab + Carboplatin · Experimental
  • Histologic-specific therapy · Active comparator
Enrollment
1,350
Primary outcomes
  • Progression-Free Survival (PFS) by blinded independent central review (BICR) in the non-squamous TROP2 biomarker positive population
  • Overall Survival (OS) in the non-squamous TROP2 biomarker positive population
  • PFS by BICR in the non-squamous population
  • OS in the non-squamous population
Sponsor
AstraZeneca
Start
Dec 29, 2022
Primary completion
Nov 1, 2027 (estimated)
Results posted
No
Registry record
NCT05687266 · updated Oct 9, 2026